



Science For A Better Life


Clinical Study Synopsis

This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment. Healthcare Professionals should always refer to the specific labelling information approved for the patient's country or region. Data in this document or on the related website should not be considered as prescribing advice. The study listed may include approved and non-approved formulations or treatment regimens. Data may differ from published or presented data and are a reflection of the limited information provided here. The results from a single trial need to be considered in the context of the totality of the available clinical research results for a drug. The results from a single study may not reflect the overall results for a drug.

The following information is the property of Bayer AG. Reproduction of all or part of this report is strictly prohibited without prior written permission from Bayer AG. Commercial use of the information is only possible with the written permission of the proprietor and is subject to a license fee. Please note that the General Conditions of Use and the Privacy Statement of bayer.com apply to the contents of this file.

| | |
|---|---|
| Title | PROTECT-AF: A Post-marketing Retrospective nOn-interventional study using naTionwide registries and electronic medical records to investigate the real-life Effectiveness and major bleeding Complications of oral anTicoagulants in Norwegian non-valvular Atrial Fibrillation patients. |
| Keywords | |
| Rationale and background | Non-vitamin K antagonist oral anticoagulants (NOACs) are approved for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) as they reduce the risk of these events. However, the anticoagulant effect of the drugs must be balanced against a risk of bleeding complications especially in patients with renal impairment and elderly who represent a large group of those affected by NVAF |
| Research question and objectives | <p>This population-based study will assess the effectiveness and safety of NOACs (rivaroxaban, dabigatran and apixaban compared to warfarin in OAC naïve NVAF patients in Norway. In addition, this study will serve as a pilot project to evaluate the ethical and operational feasibility as well as the usefulness of linking the EMR data to the Norwegian Health Registers.</p> <p>Primary objective: to assess the incidence rates of:</p> <ol style="list-style-type: none"> ischemic stroke (effectiveness) intracranial hemorrhage (safety) <p>in OAC naïve NVAF patients who are dispensed individual NOACs for the first time and compare with the corresponding rates in OAC naïve users of warfarin in a propensity score matched population.</p> <p>Secondary objectives</p> <ul style="list-style-type: none"> To assess the incidence rates of: <ul style="list-style-type: none"> overall stroke (ischemic, hemorrhagic, other unspecified) and systemic embolism outcomes; myocardial infarction; all-cause mortality; |

| | |
|---------------------|--|
| | <ul style="list-style-type: none"> major bleeding as defined by ISTH and the Cunningham algorithm (in a sub-set of patients; cohort 2) <p>in OAC naïve NVAF patients who are dispensed individual NOACs and compare with the corresponding rates in OAC naïve users of warfarin in the overall population and separately for the elderly and renally impaired patient using a propensity score matched population.</p> <ul style="list-style-type: none"> To describe and compare demographic and clinical characteristics (age, gender, CHA₂DS₂-VASc and HAS-BLED score, bleeding history, concomitant medications and co-morbidities) as well as drug utilization patterns of NVAF patients who initiated an OAC (NOACs and warfarin) in the study period. <p>Several exploratory objectives aim to assess:</p> <ul style="list-style-type: none"> differences in characteristics of NVAF patients receiving OACs or not impact of adherence to NOACs on rates of ischemic stroke and bleeding patient characteristics of NVAF patients receiving standard vs. reduced dose of NOACs and corresponding rates of ischemic stroke and bleeding in these sub-groups <p>validate data on indications and outcomes derived from the national registers using Electronic Medical Records (EMR) available for a regional sub-set of patients (cohort 2).</p> |
| Study Design | <p>This study will be a population-based retrospective cohort study on de-identified individual-level data extracted from national registers and EMRs in Norway. It will be based on two partly overlapping cohorts of patients, one utilizing only nation-wide health registers (cohort 1) and one cohort based on EMR data from selected hospitals in Norway combined with the registry data (cohort 2).</p> |
| Setting | <p>The study will be undertaken in Norway and will comprise all adult patients with NVAF who initiated treatment with either a NOAC or warfarin during the study period for the first time (OAC naïve</p> |

| | |
|--|--|
| | first-time users). Study endpoints, discontinuation, switch to another OAC, death or end of study period will serve as censoring criteria. |
| Subjects and Study Size, including dropouts | The study population will comprise all adult OAC naïve NVAf patients in Norway who filled a prescription for an OAC (rivaroxaban, apixaban, dabigatran, warfarin) in the study period, defined as from 1 January 2014 to 30 June 2018 (or later depending on availability of data). Based on the information regarding number of patients receiving listed drugs in the country, the sample size for the study will be approximately 70,000 patients. |
| Variables and Data sources | Norwegian Patient Register, Norwegian Prescription Database, and Electronic Medical Records from local hostials. |
| Results | None. Study terminated prior to data collection and data analysis. |
| Discussion | None. Study terminated prior to data collection and data analysis. |
| Marketing Authorisation Holder(s) | Bayer AG Muellerstr. 173 13353 Berlin Germany |
| Names and affiliations of principal investigators |  |